2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Polycythemia Vera (PV): new trials by email Literature Review of Polycythemia Vera (PV) trials Research Report on Polycythemia Vera (PV)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
| Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply P1101, Low-dose aspirin, Phlebotomy - Polycythemia Vera (PV) | Phase 2 | Completed | PharmaEssentia Japan K.K. | 29 | 2019-12-20 | 2025-09-15 |
Myeloproliferative Disorders (2) · Polycythemia Vera (2) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1) · Venous Thromboembolism (1)
Bone Marrow Diseases (2) · Bone Marrow Neoplasms (2) · Hematologic Diseases (2) · Hematologic Neoplasms (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Cardiovascular Diseases (1) · Embolism and Thrombosis (1) · Hemorrhagic Disorders (1) · Thrombocytosis (1) · Thromboembolism (1) · Vascular Diseases (1)
Aspirin (2) · Phlebotomy (1) · Tablets (1) · apixaban (1)
Ottawa Hospital Research Institute (1) · PharmaEssentia Japan K.K. (1)
Canada (1) · Japan (1)
Aurelien Delluc, MD, PhD (1) · Miriam Kimpton, MD (1)